化合物Acumapimod T7367
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 8
- 1
Product IntroductionBioactivity英文名: Acumapimod描述: Acumapimod (BCT-197) 是一种有口服活性的p38 MAP 激酶抑制剂，IC50值小于1 μM。动物实验: In vivo,
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: Acumapimod
描述: Acumapimod (BCT-197) 是一种有口服活性的p38 MAP 激酶抑制剂，IC50值小于1 μM。
动物实验: In vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with Acumapimod(BCT197) (a closely related p38 MAPK inhibitor with an IC50 value of<1?μM, currently in clinical testing), dexamethasone or oseltamivir (Tamiflu) starting 24?h post infection. Body weight, bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathologically[1].
体内活性: Acumapimod increases survival and reduces the number of macrophages in bronchoalveolar lavage fluid (BALF) in a mouse model of infection with influenza H1N1 A/PR/8/34 when administered at a dose of 6 mg/kg[1]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 50 mg/mL (129.73 mM)
关键字: inhibit | p38 MAPK | BCT197 | Acumapimod | Inhibitor | BCT 197 | Autophagy
相关产品: Physalin A | Dihydrocaffeic acid | EM 163 | p38 Kinase inhibitor 4 | Ro-3201195 | p38α inhibitor 3 | PP58 | Akt/NF-κB/MAPK-IN-1 | Losmapimod | SU9516
相关库: Anti-Prostate Cancer Compound Library | HIF-1 Signaling Pathway Compound Library | ReFRAME Related Library | Anti-Cancer Compound Library | Cancer Cell Differentiation Compound Library | Anti-Ovarian Cancer Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Colorectal Cancer Compound Library | Orally Active Compound Library
Bioactivity
英文名: Acumapimod
描述: Acumapimod (BCT-197) 是一种有口服活性的p38 MAP 激酶抑制剂，IC50值小于1 μM。
动物实验: In vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with Acumapimod(BCT197) (a closely related p38 MAPK inhibitor with an IC50 value of<1?μM, currently in clinical testing), dexamethasone or oseltamivir (Tamiflu) starting 24?h post infection. Body weight, bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathologically[1].
体内活性: Acumapimod increases survival and reduces the number of macrophages in bronchoalveolar lavage fluid (BALF) in a mouse model of infection with influenza H1N1 A/PR/8/34 when administered at a dose of 6 mg/kg[1]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 50 mg/mL (129.73 mM)
关键字: inhibit | p38 MAPK | BCT197 | Acumapimod | Inhibitor | BCT 197 | Autophagy
相关产品: Physalin A | Dihydrocaffeic acid | EM 163 | p38 Kinase inhibitor 4 | Ro-3201195 | p38α inhibitor 3 | PP58 | Akt/NF-κB/MAPK-IN-1 | Losmapimod | SU9516
相关库: Anti-Prostate Cancer Compound Library | HIF-1 Signaling Pathway Compound Library | ReFRAME Related Library | Anti-Cancer Compound Library | Cancer Cell Differentiation Compound Library | Anti-Ovarian Cancer Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Colorectal Cancer Compound Library | Orally Active Compound Library
猜你喜欢
感兴趣产品